Our goal is to stop the progression of serious neurodegenerative diseases with innovative therapeutic solutions.
Our goal is to stop the progression of serious neurodegenerative diseases with innovative therapeutic solutions.
About Us
Founded in 2021 as a spin-off of Universidad Pablo de Olavide (Sevilla, Spain), ONESTX bridges academic discovery and clinical drug development. By leveraging a de-risked asset with an extensive Phase I/II safety package, ONESTX delivers disease-modifying oral therapies designed to restore brain resilience, reverse cognitive decline, and transform patient outcomes. We focus primarily on Alzheimer’s and Huntington’s diseases, with broader application across the spectrum of age-related cognitive impairments.
Patent Protection & Regulatory Exclusivity:
- 3 Granted Second-Use Patent Families exclusively licensed from UPO, protecting STS inhibition and neurosteroid modulation in proteinopathic neurodegenerative diseases.
- Granted FDA Orphan Drug Designation (ODD) for Huntington’s Disease.
Corporate Credentials & Awards:
- UPO Emprende Award Winner (2023).
- Mentored by AcexHealth Accelerator (Andalusian Regional Government & PTS Granada).
- Certified Innovative SME (Pyme Innovadora) by the Spanish Ministry of Science & Innovation.
- Certified Emerging Company (Empresa Emergente) by ENISA.
Grants
Collaborative projects
Project CPP2022-009908 funded by:
Alteration of sulfated neurosteroid levels for the diagnosis and therapy of Alzheimer’s disease
(September 2023 – December 2026)
Public–private collaboration project that studies how sulfated neurosteroid levels change in Alzheimer’s disease, in order to develop new diagnostic and therapeutic approaches.
Project CPP2022-009908 funded by MICIU/AEI/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR.
Project CPP2023-010925 and Project funded by:
Therapeutic potential of a steroid sulfatase inhibitor in Huntington’s disease and its anti-neurodegenerative effect
(September 2024 – August 2027)
Public–private collaboration project that evaluates whether inhibiting steroid sulfatase can slow neurodegeneration in Huntington’s disease.
Project CPP2023-010925 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU. This project is co-funded by the European Union through the European Regional Development Fund (ERDF).
Project CPP2024-011709 funded by:
ON-MEMORY: Clinical study of safety, dose and efficacy of a drug that stabilises endogenous sulfated steroids in Alzheimer’s disease
(July 2025 – June 2028)
Public–private collaboration project that runs a clinical study to assess the safety, optimal dose and efficacy of the drug in patients with Alzheimer’s disease.
Project CPP2024-011709 funded by MICIU/AEI/10.13039/501100011033 and by ERDF/EU. This project is co-funded by the European Union through the European Regional Development Fund (ERDF).
Project NEUROSTERA funded by:
NEUROSTERA: Preclinical studies of the steroid sulfatase inhibitor STX64 in age-related diseases: pharmacokinetics–pharmacodynamics, therapeutic improvement and biomarkers of drug response
(November 2025 – November 2028).
Project NEUROSTERA funded by Corporación Tecnológica de Andalucía (CTA).
Talent Development and Recruitment
Grants Doctorados Industriales y Torres Quevedo funded by:
Grant PTQ2022-012705 funded by MICIU/AEI/10.13039/501100011033
Grant PTQ2024-013782 funded by MICIU/AEI/10.13039/501100011033
Grant PTQ2025-014423 funded by MICIU/AEI/10.13039/501100011033
Grant DIN2022-012831 funded by MICIU/AEI/10.13039/501100011033
Grant DIN2024-014198-2 funded by MICIU/AEI/10.13039/501100011033